The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment of advanced recurrent NSCLC with daily oral vinorelbine: A phase I trial.
Amanda Tufman
No relevant relationships to disclose
Astrid Borgmeier
No relevant relationships to disclose
Sylvia Guetz
Other Remuneration - Pierre Fabre Medicament
Joachim Von Pawel
No relevant relationships to disclose
Achim Rittmeyer
No relevant relationships to disclose
Rudolf M. Huber
No relevant relationships to disclose